Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a preclinical stage biotechnology company focused on developing innovative therapeutics targeting viruses, bacteria, fungi, and biofilm formations. Utilizing a unique drug-discovery platform, the company aims to create affordable and effective health solutions to combat infectious diseases and enhance healthspan.
Industries
Nr. of Employees
small (1-50)
Maxwell Biosciences
Austin, Texas, United States of America
Awards
Fiscal Year 2024 Military Prototype Advancement Initiative (MPAI)
Pathogen-Agnostic Claromer® Prophylactic to Prevent Infection in Battlefield Wounds
Funding (ceiling)
$1,853,508.15
Award Year
2024
Patents
Products
Lead peptidomimetic anti-infective candidate (nasal spray program)
A low-molecular-weight peptidomimetic developed for intranasal delivery to inactivate airborne pathogens and disrupt upper-airway biofilms; progressed through preclinical animal studies with regulatory engagement and first-in-human trials planned.
Oral peptidomimetic candidate (early-stage)
An oral small-molecule peptidomimetic program in early development targeting gastrointestinal infectious indications and microbiome imbalance.
Microbiome‑sparing cosmetic ingredient (formulation additive)
A stable small-molecule antimicrobial additive intended for integration into cosmetics and personal care products to reduce microbial contamination while preserving the skin microbiome and formulation stability.
Lead peptidomimetic anti-infective candidate (nasal spray program)
A low-molecular-weight peptidomimetic developed for intranasal delivery to inactivate airborne pathogens and disrupt upper-airway biofilms; progressed through preclinical animal studies with regulatory engagement and first-in-human trials planned.
Oral peptidomimetic candidate (early-stage)
An oral small-molecule peptidomimetic program in early development targeting gastrointestinal infectious indications and microbiome imbalance.
Microbiome‑sparing cosmetic ingredient (formulation additive)
A stable small-molecule antimicrobial additive intended for integration into cosmetics and personal care products to reduce microbial contamination while preserving the skin microbiome and formulation stability.
Expertise Areas
- Antimicrobial drug discovery
- Peptidomimetic therapeutics
- Preclinical pharmacology and toxicology
- Biofilm therapeutics
Key Technologies
- Peptoid / N-substituted glycine oligomer chemistry
- Peptidomimetic small-molecule synthesis on solid support
- Cryo-electron microscopy
- Soft X-ray tomography
News & Updates
Maxwell Biosciences has been awarded nearly $3 million from MTEC to support its research and development efforts.
The company has entered a second Cooperative Research and Development Agreement with USAMRIID to test its Claromer compounds.
CEO J. Scotch McClure has been recognized as one of the top 25 executives in the biotechnology sector.
The company reported promising results from a study showing the effectiveness of its Claromer compound against the Ebola virus.
Maxwell has entered a CRADA with USAMRIID to explore the potential of its Claromer compounds against various viral pathogens.
Maxwell Biosciences has been awarded nearly $3 million from MTEC to support its research and development efforts.
The company has entered a second Cooperative Research and Development Agreement with USAMRIID to test its Claromer compounds.
CEO J. Scotch McClure has been recognized as one of the top 25 executives in the biotechnology sector.
The company reported promising results from a study showing the effectiveness of its Claromer compound against the Ebola virus.
Maxwell has entered a CRADA with USAMRIID to explore the potential of its Claromer compounds against various viral pathogens.